title: Fibroblast growth factor 1 levels are elevated in newly diagnosed type 2 diabetes compared to normal glucose tolerance controls.
abstract: Fibroblast growth factor 1 (FGF1) has been recently characterized as a potent insulin sensitizer that regulates adipose tissue remodeling, but the physiological role of FGF1 remains unclear. This study measured serum FGF1 levels for the first time in patients with newly diagnosed type 2 diabetes mellitus (T2DM), and further explored the correlations between FGF1 levels and various metabolic parameters in T2DM. Serum FGF1 levels were determined using ELISA in age-, sex- and BMI- matched subjects with normal glucose tolerance (NGT) (n=80) and newly diagnosed T2DM (n=80). Oral glucose tolerance test (OGTT), glycosylated hemoglobin (HbA1C), blood lipids, and insulin secretion were also measured. Insulin resistance and pancreatic β-cell function were assessed by homeostasis model assessment of insulin resistance (HOMA-IR) and homeostasis model assessment of beta cell function (HOMA-β), respectively. Serum FGF1 levels were significantly higher in T2DM patients than in normal glucose tolerance subjects (74.52 [55.91∼101.34] vs. 60.31 [48.99∼83.91] pg/mL; P<0.05). In addition, serum FGF1 level positively correlated with body mass index (BMI), waist circumference (WC), waist to hip ratio (WHR), fasting plasma glucose (FPG), 2-h post-OGTT glucose (2h PG), and HbA1C (all P values <0.05) in T2DM subjects. Multivariate regression analyses showed that BMI and HbA1C were the independent factors influencing serum FGF1 levels. Logistic regression analyses demonstrated that serum FGF1 was significantly associated with type 2 diabetes (P<0.01). Circulating concentrations of FGF1 are significantly increased in T2DM patients. Our results suggest that FGF1 may play a role in the pathogenesis of T2DM.
authors.affiliation: Department of Endocrinology, Affiliated Hospital of Jiangsu University, Zhenjiang 212001, China.
authors.forename: Su
authors.initials: S
authors.lastname: Wang
authors.forename: Qichao
authors.initials: Q
authors.lastname: Yang
authors.forename: Shuqin
authors.initials: S
authors.lastname: Yu
authors.forename: Ruirong
authors.initials: R
authors.lastname: Pan
authors.forename: Dan
authors.initials: D
authors.lastname: Jiang
authors.forename: Yuanxin
authors.initials: Y
authors.lastname: Liu
authors.forename: Hao
authors.initials: H
authors.lastname: Hu
authors.forename: Wenjun
authors.initials: W
authors.lastname: Sun
authors.forename: Xiafei
authors.initials: X
authors.lastname: Hong
authors.forename: Haoying
authors.initials: H
authors.lastname: Xue
authors.forename: Weiyun
authors.initials: W
authors.lastname: Qian
authors.forename: Dong
authors.initials: D
authors.lastname: Wang
authors.forename: Libin
authors.initials: L
authors.lastname: Zhou
authors.forename: Chaoming
authors.initials: C
authors.lastname: Mao
authors.forename: Guoyue
authors.initials: G
authors.lastname: Yuan
mesh_terms: D000328:Adult; D001786:Blood Glucose / Q000378:metabolism; D016022:Case-Control Studies; D003924:Diabetes Mellitus, Type 2 / Q000097:blood* / Q000175:diagnosis; D005260:Female; D016220:Fibroblast Growth Factor 1 / Q000097:blood*; D005951:Glucose Tolerance Test; D006801:Humans; D008297:Male; D008875:Middle Aged; D013997:Time Factors; D015854:Up-Regulation
chemical_list: D001786:Blood Glucose; D016220:Fibroblast Growth Factor 1